Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?

Vertex Pharmaceuticals (VRTX 1.88%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or sur ...